Chaim Lebovits - Apr 17, 2024 Form 4/A Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role
President & CEO
Signature
/s/ Chaim Lebovits
Stock symbol
BCLI
Transactions as of
Apr 17, 2024
Transactions value $
$131,411
Form type
4/A
Date filed
7/31/2024, 04:05 PM
Date Of Original Report
Apr 19, 2024
Previous filing
Mar 13, 2024
Next filing
Apr 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCLI Common Stock Purchase $70.9K +130K +21.72% $0.55 728K Apr 17, 2024 Direct F1, F2
transaction BCLI Common Stock Purchase $60.5K +115K +15.8% $0.53 844K Apr 18, 2024 Direct F1, F3
holding BCLI Common Stock 2M Apr 17, 2024 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'.
F2 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 67,053 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.